medigraphic.com
ISSN 1561-3054 (Electronic)

2021, Number 1

<< Back Next >>

Rev Cubana Med Trop 2021; 73 (1)

Kaposi sarcoma in patients living with HIV in Equatorial Guinea

Barja LJM, Nzi NM, Vargas BA

Language: Spanish
References: 24
Page: 1-14
PDF size: 497.01 Kb.


ABSTRACT

Introduction: Kaposi sarcoma is an opportunistic neoplasm associated to the immunosuppression caused by HIV and related to infection by HHV-8.
Objective: Describe the presentation of Kaposi sarcoma in people living with HIV in Equatorial Guinea.
Methods: A retrospective descriptive study was conducted to identify the prevalence and the clinical and epidemiological characteristics of Kaposi sarcoma in people living with HIV attending reference units for the management of cases in Equatorial Guinea. A review was carried out of the medical records of a random sample representative of 338 patients from the group receiving treatment at Bata reference unit for infectious diseases from January 2007 to February 2012.
Results: A total 40 patients diagnosed with Kaposi sarcoma were identified (prevalence of 11,83%). Mean age at Kaposi sarcoma diagnosis was 43 years, with a 1/1 sex ratio. The mean CD4 lymphocyte count at diagnosis was 166 (range 21-375), whereas the frequency of oral damage was 45%. In most patients (94.6%) detection of Kaposi sarcoma was prior to the start of antiretroviral therapy. CD4 T lymphocyte levels / mm3 below 100 were mainly found in patients aged under 30 years, a fact particularly frequent among women (OR 11, p< 0.04, CI 95% 0.8-148).
Conclusions: Kaposi sarcoma is a neoplasm prevailing in people living with HIV who attend reference units in Equatorial Guinea. Late diagnosis could exist among women aged under 30 years.


REFERENCES

  1. Schneider JW, Dittmer DP. Diagnosis and Treatment of Kaposi Sarcoma. Am J Clin Dermatol. Aug 2017;18(4):529-39.

  2. Pfeiffer RM, Wheeler WA, Mbisa G, Whitby D, Goedert JJ, de Thé G, et al. Geographic heterogeneity of prevalence ofthe human herpesvirus 8 in subsaharan Africa: clues about etiology. Ann Epidemiol. Dec 2010;20(12):958-63.

  3. Ruocco V, Ruocco E, Schwartz RA, Janniger CK. Kaposi sarcoma and quinine: a potentially overlooked triggering factor in millions of Africans. J Am Acad Dermatol. 2011 Feb;64(2):434-6.

  4. Rezza G, Tchangmena OB, Andreoni M, Bugarini R, Toma L, Bakary DK, et al. Prevalence and risk factors for human herpesvirus 8 infection in northern Cameroon. Sex Transm Dis. 2000 Mar;27(3):159-64.

  5. Uldrick TS, Whitby D. Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma. Cancer Lett. 28 Jun 2011;305(2):150-62.

  6. Friedman-Kien AE, Saltzman BR. Clinical manifestations of classical, endemic African, and epidemic AIDS-associated Kaposi's sarcoma. J Am Acad Dermatol. 1990 Jun;22(6 Pt 2):1237-50.

  7. Rees CA, Keating EM, Lukolyo H. Mapping the epidemiology of Kaposi sarcoma and non-Hodgkin lymphoma among children in subSaharan Africa: a review. Pediatr Blood Cancer. 2016;63(8):1325-31.

  8. Maurer T, Ponte M, Leslie K. HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. N Engl J Med. 2007 Sep 27;357(13):1352-3.

  9. Mosam A, Hurkchand HP, Cassol E, Page T, Cassol S, Bodasing U, et al. Characteristics of HIV-1-associated Kaposi's sarcoma among women and men in South Africa. Int J STD AIDS. 2008 Jun;19(6):400-5.

  10. Chu KM, Mahlangeni G, Swannet S, Ford NP, Boulle A, Van Cutsem G. AIDS-associated Kaposi's sarcoma is linked to advanced disease and high mortality in a primary care HIV programme in South Africa. J Int AIDS Soc. 2010 Jul 8;13:23.

  11. Krown SE. Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunities. Curr Opin Oncol. 2011 Sep;23(5):463-8.

  12. Bekolo CE, Soumah MM, Tiemtore OW, Diallo A, Yuma JD, Di Stefano L, et al. Assessing the outcomes of HIV-infected persons receiving treatment for Kaposi sarcoma in Conakry-Guinea. BMC Cancer. 2017 Dec 2;17(1):806.

  13. Macken M, Dale H, Moyo D, Chakmata E, Depani S, Israels T, et al. Triple therapy of vincristine, bleomycin and etoposide for children with Kaposi sarcoma: Results of a study in Malawian children. Pediatr Blood Cancer. Feb 2018;65(2).

  14. Phipps W, Ssewankambo F, Nguyen H, Saracino M, Wald A, Corey L, et al. Gender differences in clinical presentation and outcomes of epidemic Kaposi sarcoma in Uganda. PLoS One. 2010 Nov 12;5(11):e13936.

  15. Mosam A, Hurkchand HP, Cassol E, Page T, Cassol S, Bodasing U, et al. Characteristics of HIV-1-associated Kaposi's sarcoma among women and men in South Africa. Int J STD AIDS. 2008 Jun;19(6):400-5.

  16. Letang E, Almeida JM, Miró JM, Ayala E, White IE, Carrilho C, et al. Predictors of immune reconstitution inflammatory syndrome-associated with kaposi sarcoma in Mozambique: a prospective study. J Acquir Immune Defic Syndr. 2010 Apr;53(5):589-97.

  17. Iregbu KC, Elegba OY. Prevalence of Kaposi's sarcoma among adult HIV-seropositive patients seen in adesignated HIV treatment and care center in Abuja, Nigeria. J Int Assoc Physicians AIDS Care (Chic). 2006 Sep;5(3):115-8.

  18. Asiimwe F, Moore D, Were W, Nakityo R, Campbell J, Barasa A, et al. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda. HIV Med. 2012 Mar;13(3):166-71.

  19. UNDP. Africa human development report 2016 accelerating gender equality and women's empowerment in Africa. New York: United Nations Development Programme; 2016

  20. Díaz Torres HM, Lubián Caballero AL. Definición de caso y clasificación de la infección por VIH y SIDA. Rev Cubana Med. 1998 Sep;37(3):157-65.

  21. Crum-Cianflone NF, Hullsiek KH, Ganesan A, Weintrob A, Okulicz JF, Agan BK; Infectious Disease Clinical Research Program HIV Working Group. Is Kaposi's sarcoma occurring at higher CD4 cell counts over the course of the HIV epidemic? AIDS. 2010 Nov 27;24(18):2881-3.

  22. Maurer T, Ponte M, Leslie K. HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. N Engl J Med. 2007 Sep 27;357(13):1352-3.

  23. Ravera M, Reggiori A, Cocozza E, Andreata M, Ciantia F. Kaposi's sarcoma and AIDS in Uganda: its frequency and gastrointestinal distribution. Ital J Gastroenterol. 1994 Sep;26(7):329-33.

  24. Chu KM, Mahlangeni G, Swannet S, Ford NP, Boulle A, Van Cutsem G.AIDS- associated Kaposi's sarcoma is linked to advanced disease and highmortality in a primary care HIV programme in South Africa. J Int AIDS Soc. 8 Jul 2010;13:23.




2020     |     www.medigraphic.com